Conditioning therapy with N‐acetyl‐L‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26903
Abstract: Conditioning therapy is an essential procedure prior to hematopoietic stem cell transplant (HSCT), imposing a great impact on the outcomes of recipients. We performed a prospective randomized controlled trial to assess the outcome of HSCT… read more here.
Keywords: arm; decitabine; myeloid malignancies; therapy ... See more keywords
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2024 at "Hematological Oncology"
DOI: 10.1002/hon.3274
Abstract: Venetoclax, a highly selective BCL‐2 inhibitor, combined with hypomethylating agents (HMAs) azacitidine or decitabine, is approved for the treatment of newly diagnosed acute myeloid leukemia (ND AML) in patients who are ineligible to receive intensive… read more here.
Keywords: venetoclax plus; acute myeloid; decitabine; study ... See more keywords
Decitabine inhibits tumor cell proliferation and up‐regulates e‐cadherin expression in Epstein–Barr virus‐associated gastric cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Virology"
DOI: 10.1002/jmv.24634
Abstract: The present study investigated the effect of a DNA demethylating agent, decitabine, against Epstein–Barr virus‐associated gastric cancer (EBVaGC). Decitabine inhibited cell growth and induced G2/M arrest and apoptosis in EBVaGC cell lines. The expression of… read more here.
Keywords: epstein barr; decitabine; barr virus; virus associated ... See more keywords
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-3185-5
Abstract: In contrast to the evidence regarding azacitidine (Aza), there is limited knowledge about the combination of decitabine (DAC) and donor lymphocyte infusions as salvage therapy for relapse after allogeneic stem cell transplantation (allo-SCT) so far.… read more here.
Keywords: aml mds; dac; cell transplantation; decitabine ... See more keywords
Efficacy of decitabine as hemoglobin F inducer in HbE/β-thalassemia
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3357-y
Abstract: To study safety, efficacy (hemoglobin and hemoglobin F percentage increment in non-transfusion-dependent patients and decrease in transfusion frequency in transfusion-dependent patients), and determinants of response of decitabine in patients with HbE/β-thalassemia. Thirty patients of HbE/β-thalassemia… read more here.
Keywords: decitabine; transfusion dependent; hbe thalassemia; hemoglobin ... See more keywords
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-06033-y
Abstract: The treatment of older patients with acute myeloid leukemia (AML) considered unfit for receiving intensive chemotherapy is challenging. Based on the hypothesis that addition of the broad tyrosine kinase inhibitor (TKI) midostaurin could improve the… read more here.
Keywords: aml; decitabine; midostaurin; intensive chemotherapy ... See more keywords
Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00854-9
Abstract: Purpose The objective of this mass balance trial was to determine the excretory pathways and metabolic profile of the novel anticancer agent guadecitabine in humans after administration of a 14C-radiolabeled dose of guadecitabine. Experimental design… read more here.
Keywords: mass balance; guadecitabine; 14c guadecitabine; mass ... See more keywords
Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasis
Sign Up to like & getrecommendations! Published in 2024 at "Medical Oncology"
DOI: 10.1007/s12032-024-02320-w
Abstract: Myeloid-derived suppressor cells (MDSCs) play a crucial role in promoting melanoma metastasis. Reprogramming MDSCs into mature M1 macrophages has emerged as a strategy to inhibit metastasis. Decitabine (Dec) is known to eradicate MDSCs and suppress… read more here.
Keywords: melanoma metastasis; functional mechanism; dec; dual functional ... See more keywords
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01948-8
Abstract: Decitabine (5-aza-2′-deoxycytidine) is a hypomethylating agent used in the treatment of acute myeloid leukemia (AML). Decitabine inhibits DNA methyltransferases, causing DNA hypomethylation, and limiting the transcription of tumor suppressor genes, leading to gene silencing. Decitabine… read more here.
Keywords: myeloid leukemia; treatment; monotherapy patients; decitabine ... See more keywords
Therapeutic effect of TRC105 and decitabine combination in AML xenografts
Sign Up to like & getrecommendations! Published in 2020 at "Heliyon"
DOI: 10.1016/j.heliyon.2020.e05242
Abstract: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refractory AML patients, yet responses… read more here.
Keywords: combination; dac; decitabine; aml xenografts ... See more keywords
Role of Maintenance Therapy with Decitabine in Acute Myeloid Leukemia in First Remission: A Prospective Interventional Study from a Tertiary Care Center in Eastern India
Sign Up to like & getrecommendations! Published in 2025 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0045-1811939
Abstract: Abstract Introduction Major advances in the diagnostic methodologies and technological progress have led to successful development of many targeted agents in the management of acute myeloid leukemia (AML). At present, standard of care of AML… read more here.
Keywords: maintenance; acute myeloid; remission; decitabine ... See more keywords